{"id":935806,"date":"2026-02-10T16:34:07","date_gmt":"2026-02-10T21:34:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/"},"modified":"2026-02-10T16:34:07","modified_gmt":"2026-02-10T21:34:07","slug":"dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/","title":{"rendered":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"right\"> Ch\u00e2tillon, France, February 10, 2026<\/p>\n<p align=\"justify\">\n        <b>DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting<\/b>\n      <\/p>\n<p align=\"justify\">DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN\u00ae Peanut Patch in children ages 4-7 years from the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A3V4bj9O4aD5rIBX1jmPE_ftLkgvUqLWrHwChJLq6fqkWPKV-aO3vlTmEekt1XkrSq9ef8qZR-qhYUYp_i_MSABeO8g9BqEe-A8mka-5c5tUpWxHmwUnqryETTb8ne2Y7t6WUsnKrndXbVTIC4BSgYTUrmS-gEJildNBbPRmCDIMLrxLMauxn1fLgABr5uVd1skGAd1N3pxAepGXRk1Q6IRwC-uLw1gF6LiRmZ-2ljHgPeMKimvlwYAdlXsjMM4kxwnMgSE8oyOAox6UdnLvmoCsznJpQt8HmeYH19U3zYK554ZEDUWh5ENZi6mT6CWnfsn9JPjfhmambs9LnjBhCGWEmL5u8yVT_MTSV44f-YPMbkuAXq_tOjExXcV4G4PX5o2jfQAVxyEYBYXC62M69nd4YCKP884yzjjN2Emc5XB9eF5hdgaPPLzzbCbpyyzantsYzzXuGdIXeYecqBFH28lpiDaEOlq9SJglPbv1j9pM8AX5zlSQ0Xj_LKdmX2d6aW4zR4EFN7ZzifRBj5tZFl2vCu8Ka6sb8Qu8cJdjGgBMw6OgToHxj7o3A1XR_S4APRoK9DBpipAWT4mb5-mRGF9TjvlqxQ1pyqAeb95fSOFimt-ntAULd_8Pu1-hF5aU\" rel=\"nofollow\" target=\"_blank\">positive VITESSE Phase 3 study<\/a> at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026.<\/p>\n<p align=\"justify\">The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential of epicutaneous immunotherapy (EPIT) to reeducate the immune system in food allergy, examine the impact of early intervention in children with peanut allergy, and consider how emerging treatment options are enabling for a more proactive approach to peanut allergy management.<\/p>\n<p align=\"left\">\n        <b>Oral Abstract Presentation Details<\/b><br \/>\n        <br \/>\n        <b>\u201cVITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age\u201d<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Session: Clinical Science in Food Allergy<\/li>\n<li style=\"text-align:justify\">Date and Time: February 28, 2026, 2:15-2:25pm ET<\/li>\n<li style=\"text-align:justify\">Location: Level 4, Terrace Ballroom II <\/li>\n<li style=\"text-align:justify\">Presenter: David Fleischer, MD, FAAAAI, FACAAI<\/li>\n<\/ul>\n<p align=\"left\">\n        <b>Product Theater Details<\/b><br \/>\n        <br \/>\n        <b>\u201cEpicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment\u201d<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Date and Time: February 28, 2026, 10:00-10:30am ET<\/li>\n<li style=\"text-align:justify\">Location: Level 2, Hall E<\/li>\n<li style=\"text-align:justify\">Participants: Hugh Sampson, MD, Katherine Anagnostou, MD, MSc, PhD, S. Shahzad Mustafa, MD\n<\/li>\n<\/ul>\n<p align=\"justify\">DBV will exhibit at booth #1527 in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy and the VIASKIN<sup>\u00ae<\/sup> Peanut Patch.<\/p>\n<p align=\"left\">\n        <b>About DBV Technologies<\/b><br \/>\n        <br \/>DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN\u00ae patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN\u00ae patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual\u2019s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin\u2019s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company\u2019s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).<\/p>\n<p align=\"justify\">DBV Technologies is headquartered in Ch\u00e2tillon, France, with North American operations in Warren, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT \u2013 CUSIP: 23306J309).<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q_55xxQCCBiYZuBEVTmN5VtMoE2z7FS1cpp3LltXYUCtdz860xez3UDIVofMMn3i5Xg8Crua7pF8SMe0WQsnud-aYumQyas0MXLzKGYFBE6vcFYiMpDCvZMrAiVSDXo_uNmaQQ9ZzFERtZKlYa3AlgiZ6anN1n8D8z-ThvPlPKn_oTIhihMvi_o9UwhjzSThsKhNLSgoRJMw0oe0UJwNkfOn3scC1iK9gacfQxzPXJYpYHQAAaXBfrOELS_LswhHMh0zOQZuRtg7Cf4fwI54NulcqIR9cYG1YfNCVYMXCeZtwm44ob_sMPCWLNRNE8N0_75aBy_KoBpoC62Fhfd0V_TVi55WeMKArqhnBY_jZCE-6gPNMLpCZLtGoyqcFO6XD92gL7fM0-Zs9lvVKTigqrrrgGCuIK3NEw4CybWvbsY=\" rel=\"nofollow\" target=\"_blank\">www.dbv-technologies.com<\/a> and engage with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k7iBnZEOv86NkQZ9nLZ6Z75h4VvQXgi4mTpROKcTxBgS6oiqNDOOBF7WMXYxIoIFCWN5SqfXYra_bZ6ZtqTfSMQDSRvGTP5RrBeSoiOo3sAwGmlJVlMbJcoS2v6TOCvUlOJeimrWJQeIDs6IScQJbVoBVfBsYFUxa65S9ijrwaw4u11cC3a61I8WSd9cRWsI5fH6YCmNL2UbSdZv6Iq-dHTNE5XNN3z0u5mgamUMOOZEk9J94g3MFG-qyEx1jMzX_RsNTFq1qKSC_lASEaHuCBf61ue5q3NSR8Ba4ZtT-kJpCaImaUuatIB6BbiXXQgp-Kna1-xGVfGwEXpoi3DlcmA_gvwXVoUYIUGToPFCGrg2qchIOtZLBDVASObQMAQQFKoI1jK65S6IOSjBYX7a1ocpksDeEEs-PwLLCPFpZY4=\" rel=\"nofollow\" target=\"_blank\">X (formerly Twitter)<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VgdhB3ZximM89n8qZ3whRvgnR7MXOsGRI-x1vrqvUoGJYM_FsvgwlkeIXppbpvE92cnvoUVYY7wk-n7oDh3D3VrFF6HSNLqQr0hcWYiDZrLHb_UTJYhe-bBwzKSeEJfio7PgYIpIreNne0W0dMBU_667T3e2fpdfdhEH7QPVAqHssDf52A_UlIx0-y_B4Kp49PSN15dC8LrmkYp-sslqTXuHULKB0im19bHUx6pG1My_FAgyZ4j4mBq0v8CbDjDBau3D6urvxy8bwmfMcJpjxec-SU_qaCbl00vL44VzpA3LvBF4DMNA6pQv8tltsn-LAIaWaM7PYEpdHAwWy1_rBoRlIK0bt1WOvlgYn3SzI71mKvpBmK45h1x0SIIqmR5OSUDW7lUKVbJObUFC4xwbNPCuAJ7NmxveCI7dCZgh4IU=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>. <\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b><br \/>\n        <br \/>This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN\u00ae Peanut patch and EPIT, results of DBV\u2019s clinical trials, DBV\u2019s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, and the ability of any of DBV\u2019s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV\u2019s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV\u2019s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV\u2019s regulatory filings with the French Autorit\u00e9 des March\u00e9s Financiers (\u201cAMF\u201d), DBV\u2019s filings and reports with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including in DBV\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K\/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K\/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.<\/p>\n<p align=\"justify\">VIASKIN is a registered trademark of DBV Technologies.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b><br \/>\n        <br \/>Jonathan Neely<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EnlJfOWasHmmo0A_x8slZHqcFbAx0nviPSXXhSAfN18K7SbbmP7r-g8Mre7vWPiK0PUl6-RSlRqFsa8Gnx54dyFej9ICzibW7kOSvo9lck3KercYlH8qymvczRsvC0K2zaDbTzKb5IY-FcM-0Gwy1A==\" rel=\"nofollow\" target=\"_blank\">jonathan.neely@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\">\n        <b>Media Contact<\/b><br \/>\n        <br \/>Brett Whelan<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xo-Ugpvt5qv92F7kfVgkAiCDxA59ef9ACIRZ5PS79fOr43rDlAMuKO1S_hVrnqZMtNoqjc2skxzDFXfc2Y789RKgJKhvkouFw4qD_-OU22o-TtqqeYl3Z60gYt0CgK9UkIwKe67MMW-FEX_nVNBK8A==\" rel=\"nofollow\" target=\"_blank\">brett.whelan@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/df9f19c7-f881-40cc-b8e2-2424abb527b9\">PDF Version<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NDk4OGZiYjctNzQ3NS00ZDNkLWJhNjctZGJjOTZmNjUwMTAwLTEwMTExNTItMjAyNi0wMi0xMC1lbg==\/tiny\/DBV-Technologies-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ch\u00e2tillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN\u00ae Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026. The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935806","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ch\u00e2tillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN\u00ae Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026. The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential &hellip; Continue reading &quot;DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T21:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting\",\"datePublished\":\"2026-02-10T21:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/\"},\"wordCount\":896,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/\",\"name\":\"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\",\"datePublished\":\"2026-02-10T21:34:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/","og_locale":"en_US","og_type":"article","og_title":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk","og_description":"Ch\u00e2tillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN\u00ae Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026. The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential &hellip; Continue reading \"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T21:34:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting","datePublished":"2026-02-10T21:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/"},"wordCount":896,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/","name":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==","datePublished":"2026-02-10T21:34:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDA2MiM0MDIzMzA3MzMjMTAxMTE1Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin-peanut-patch-in-children-ages-4-7-years-and-discuss-future-of-epit-in-the-treatment-landscape-at-aaaai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN\u00ae Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI\u00a02026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935806"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}